

Review

Schmallenberg Virus: Pathogenesis, Diagnostic Challenges, and Control Gap in Endemic Europe

Silvia Preziuso ¹, Anna-Rita Attili ¹, Chiara Storoni ¹, Lorenza Di Perna ¹, Yubao Li ²
and Vincenzo Cuteri ^{1,2,*}

¹ School of Biosciences and Veterinary Medicine, University of Camerino, 62024 Matelica, Italy; silvia.preziuso@unicam.it (S.P.); annarita.attili@unicam.it (A.-R.A.); chiara.storoni@unicam.it (C.S.); lorenza.diperna@studenti.unicam.it (L.D.P.)

² School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng 252000, China; liyubao@lcu.edu.cn

* Correspondence: vincenzo.cuteri@unicam.it; Tel.: +39-073-740-4001

Abstract

Schmallenberg virus (SBV) has evolved from an emergent *Orthobunyavirus* identified in Europe in 2011 into an endemic pathogen with complex epidemiological dynamics. This review focuses on three key aspects: pathogenesis and fetal neurotropism, diagnostic limitations within the Simbu serogroup, and challenges in disease control. SBV pathogenesis is characterized by immune evasion mediated by the NSs protein and a marked tropism for the developing central nervous system, resulting in congenital malformations when infection occurs during critical gestational stages. Similar mechanisms are shared with other Simbu serogroup viruses, contributing to overlapping clinical presentations and complicating differential diagnosis. Diagnostic approaches are constrained by the short duration of viraemia and significant serological cross-reactivity among related viruses. While RT-qPCR is effective for detecting acute infections, its utility is limited for retrospective diagnosis, where fetal tissues and pre-colostral serology are required. Widely used ELISAs lack serogroup specificity, raising concerns about the potential under-recognition of co-circulating or emerging viruses. Despite advances in vaccine development, implementation remains limited, and vector control strategies provide only partial mitigation. SBV therefore represents a valuable model for understanding arbovirus persistence in temperate regions. Addressing current challenges will require improved diagnostic specificity, sustainable vaccination strategies, and integrated surveillance systems.

Keywords: Schmallenberg virus; Simbu serogroup; *Culicoides*; arbovirus epidemiology; congenital malformations; diagnostic limitations; vaccine uptake; climate change



Academic Editors: Wataru Mitsuhashi
and Erna G. Kroon

Received: 27 March 2026

Revised: 28 May 2026

Accepted: 7 June 2026

Published: 9 June 2026

Corrected: 27 July 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

1. Introduction: Schmallenberg Virus as a Model of Endemic Arbovirus Persistence

Since its emergence in Europe in 2011, Schmallenberg virus (SBV) has transitioned from an acute epidemic threat to an endemic arbovirus characterized by recurrent, wave-like transmission dynamics. Initially identified in dairy cattle in Germany presenting with transient fever, reduced milk production, and diarrhea, SBV rapidly spread across Europe within a single vector season, demonstrating that temperate regions can sustain the emergence and persistence of novel arboviruses when competent vectors and susceptible host populations are present [1–3].

SBV belongs to the Simbu serogroup within the genus *Orthobunyavirus*, family *Peribunyaviridae*. This serogroup includes several antigenically and genetically related viruses of veterinary importance, such as Akabane virus, Aino virus, Shamonda virus, Peaton virus, Shuni virus, and others [4,5]. These viruses share key biological features, including a tripartite negative-sense RNA genome, transmission by *Culicoides* biting midges, and—for several members—the ability to cause congenital malformations when naïve pregnant ruminants are infected during critical stages of gestation [6].

The clinical importance of SBV lies less in acute disease in adult animals, which is usually mild, transient, or subclinical, and more in its teratogenic potential. Infection of naïve pregnant ruminants during defined gestational windows can result in transplacental transmission, fetal central nervous system damage, arthrogryposis, hydranencephaly, abortion, stillbirth, or the birth of non-viable malformed offspring [5,7,8].

Importantly, the congenital syndrome caused by SBV is not pathognomonic. Several Simbu serogroup viruses produce overlapping clinical and pathological outcomes, particularly the arthrogryposis–hydranencephaly complex [5,7]. This creates important diagnostic and surveillance challenges, especially in regions where multiple Simbu serogroup viruses may circulate simultaneously. In such settings, reliance on broadly reactive serological assays may obscure the emergence or re-emergence of related viruses and may lead to under-recognition of mixed or sequential circulation events [9,10].

Fifteen years after its first detection, SBV provides a useful model for understanding arbovirus emergence, endemic persistence, and control in temperate livestock systems. Its epidemiology is shaped by the interaction of vector ecology, livestock immunity, animal trade, climate variability, diagnostic capacity, and vaccine availability [2,3,6,11]. The following sections examine three areas where current knowledge gaps have direct implications for disease control: pathogenesis and fetal neurotropism, diagnostic limitations within the Simbu serogroup context, and practical constraints affecting vaccination and vector management.

2. Pathogenesis and Disease Mechanisms: From Vector Transmission to Fetal Damage

2.1. Transmission and Early Host Infection

SBV is transmitted predominantly by infected *Culicoides* biting midges. Following inoculation during blood feeding, the virus initially replicates at or near the site of entry and in associated lymphoid tissues before disseminating through the bloodstream [11–13]. In adult ruminants, this results in a short viremic phase, usually lasting only a few days, which explains both the transient nature of acute disease and the narrow diagnostic window for molecular detection in blood [8,14].

Clinical signs in adult cattle, sheep, and goats are generally non-specific and may include fever, diarrhea, reduced appetite, and decreased milk production [1,15]. However, the major pathogenic consequence of maternal infection occurs when viraemia coincides with pregnancy, allowing the virus to reach the placenta and infect the developing fetus [7,8,16].

2.2. Transplacental Transmission and Fetal Infection

A defining feature of SBV and several related Simbu serogroup viruses is the capacity for transplacental transmission. After maternal viraemia, SBV can infect placental tissues and subsequently enter the fetal circulation [7,8,16]. The consequences of fetal infection depend strongly on gestational age, because susceptibility is linked to the developmental stage of the fetal immune and nervous systems [5,7].

2.3. Neurotropism and the Mechanisms of Congenital Malformations

SBV shows marked tropism for fetal neural tissues. Experimental and field studies have demonstrated viral antigen and RNA predominantly in neurons of the brain and spinal cord, particularly in grey matter [7,16,17]. Viral replication in these cells leads to neuronal degeneration, necrosis, cerebral malacia, and disruption of normal CNS development [7,16,17].

The characteristic musculoskeletal lesions, especially arthrogryposis, are secondary to CNS damage rather than the result of primary viral replication in muscle. Destruction of spinal motor neurons disrupts neuromuscular signaling, leading to neurogenic muscle atrophy, reduced fetal movement, and fixed limb contractures [5,7]. This mechanism closely resembles that described for Akabane virus and other teratogenic Simbu serogroup viruses [5,6] (Figure 1).




Figure 1. Cellular and molecular pathogenesis of SBV.

Because these lesions are shared across several Simbu viruses, clinical presentation alone cannot reliably distinguish SBV from Akabane, Aino, Shamonda, Peaton, or Shuni virus infections. Laboratory confirmation is therefore essential, particularly in areas where multiple Simbu serogroup viruses may circulate [5,6,9,10].

2.4. NSs-Mediated Immune Evasion

The non-structural protein NSs is a major SBV virulence factor. Reverse genetics studies have shown that deletion of NSs markedly attenuates SBV, confirming its importance in viral pathogenesis. NSs antagonizes the host type I interferon response by interfering with host transcriptional machinery, thereby suppressing interferon and interferon-stimulated gene expression [18,19] (Figure 2). This immune evasion strategy allows SBV to establish systemic infection despite early innate immune defenses. Similar NSs-mediated interferon antagonism has been described for other orthobunyaviruses, indicating that suppression of the innate antiviral response is a conserved mechanism within this group [4,18,19].




Figure 2. Schmallenberg virus transmission and pathogenesis. **(A)** Schmallenberg virus (SBV) is maintained in nature through a transmission cycle between infected *Culicoides* biting midges and susceptible ruminants. Vector activity and transmission are influenced by temperature and seasonality. **(B)** After a midge bite, SBV replicates locally and causes a short viraemia. During pregnancy, the virus can cross the placenta and infect the fetus, with a marked tropism for the developing central nervous system. Infection during critical gestational windows may result in congenital malformations such as hydranencephaly, porencephaly, and arthrogryposis. The viral NSs protein inhibits the host interferon response, thereby enhancing viral replication.

2.5. Gestational Timing and Lesion Spectrum

The type and severity of lesions depend strongly on the timing of fetal infection. Earlier fetal infection is more likely to cause severe CNS destruction, including hydranencephaly and porencephaly, whereas later infection more commonly results in arthrogryposis, spinal cord lesions, or milder neurological signs [5,7,8].

In cattle, infections occurring approximately between 80 and 120 days of gestation are commonly associated with severe cerebral lesions, while infections later in gestation may produce arthrogryposis, scoliosis, torticollis, or calves born alive with neurological deficits [5,8]. In sheep and goats, the shorter gestational period shifts the equivalent susceptibility window earlier [5].

A useful pathological feature in the differential diagnosis of Simbu serogroup infections is the relative absence of cerebellar lesions, which can help distinguish these infections from other teratogenic viruses such as bovine viral diarrhea virus [5].

Comparative Analysis of Gestational Windows Across Ruminant Species

The differences in susceptibility windows between ruminant species reflect species-specific rates of fetal neurodevelopment and maturation of the blood–brain barrier. In sheep, the compressed gestational period (~147 days) and early development of spinal motor neurons (peak vulnerability days 28–42) create a narrower window. In cattle (~282 days gestation), the extended period of cerebellar and cerebral cortical development (~80–150 days) produces a broader window. Goats (~150 days gestation) show patterns similar to sheep, though data are more limited [5]. Comparative neurodevelopmental studies indicate that the timing of oligodendrocyte precursor differentiation and blood–brain barrier tight junction formation correlates with susceptibility to SBV-induced lesions across species.

Species-specific differences in placental trophoblast expression of viral entry receptors (yet to be fully characterized) may also contribute.

Table 1 summarizes the key gestational parameters.

Table 1. Gestational parameters and lesion timing in SBV infection.

Species	Gestation Length (Days)	Critical Window (Days)	Peak Neuronal Vulnerability	Primary Lesion Type If Infected Early vs. Late
Cattle	~282	80–150	Cortical neurogenesis (80–120)	Early: hydranencephaly; Late: arthrogryposis
Sheep	~147	28–56	Spinal motor neurons (28–42)	Early: porencephaly; Late: arthrogryposis
Goat	~150	30–60 (estimated)	Similar to sheep	Limited data; pattern presumed similar to sheep

2.6. SBV Within the Broader Simbu Serogroup Context

SBV should not be considered in isolation. Although SBV is currently the principal Simbu serogroup virus recognized in Europe, related viruses have caused similar congenital syndromes in Asia, Africa, Australia, and the Middle East [5,6,10]. Some, such as *Akabane* virus, are well-established teratogenic pathogens, whereas others, including *Shuni* and *Shamonda* viruses, have been increasingly recognized in association with neurological disease or congenital abnormalities [6,10,20,21]. In particular, *Shuni* virus has been associated with fatal encephalitis in calves [22].

Antigenic relationships among Simbu serogroup viruses are complex. The nucleocapsid (N) protein is highly conserved (~85–95% amino acid identity across the serogroup), explaining the extensive cross-reactivity observed in N-based ELISAs. In contrast, the surface glycoproteins Gn and Gc show greater diversity (~60–75% identity), and neutralizing antibody responses are largely type-specific. Phylogenetic analysis places SBV within the Simbu serogroup's 'Simbu-like' clade, most closely related to *Sathuperi* and *Shamonda* viruses. The Gc protein, which mediates host cell attachment and membrane fusion, contains variable domains that determine serotype specificity.

Table 2 provides a systematic comparison of selected Simbu serogroup viruses.

Table 2. Comparative features of selected Simbu serogroup viruses of veterinary importance.

Feature	SBV	Akabane Virus	Shuni Virus	Aino Virus	Shamonda Virus
Geographic distribution	Europe	Africa, Asia, Australia, Middle East	Africa, Middle East	Asia, Africa	Africa, Asia
Primary livestock impact	Cattle, sheep, goats	Cattle, sheep, goats	Cattle, sheep	Cattle	Cattle
Congenital malformation risk	High	High	Documented	High	Documented
Abortion/stillbirth reported	Yes	Yes	Yes	Yes	Yes
Adult clinical disease	Mild/febrile	Usually subclinical	Neurologic (calves)	Subclinical	Subclinical
Diagnostic cross-reactivity (ELISA)	High	High	High	High	High
VNT distinguishability	Yes	Yes	Yes	Yes	Yes
Vaccine cross-protection	Limited	Limited	Unknown	Unknown	Unknown
NSs immune evasion documented	Yes	Yes	Presumed	Yes	Presumed
Confirmed in Europe	Yes	No (serological only)	No	No	No

This broader context has two important consequences. First, the clinical and pathological overlap among Simbu serogroup viruses requires diagnostic approaches capable of distinguishing between them. Second, serological cross-reactivity may lead to under-detection of emerging or co-circulating viruses if surveillance relies only on non-specific commercial ELISAs [9,10]. For this reason, virus neutralization tests and molecular assays remain essential tools for specific identification in areas where multiple Simbu serogroup viruses may be present [9,10].

3. Epidemiology in an Endemic System: Vector Ecology, Trade, and Cyclic Re-Emergence

The endemic epidemiology of SBV reflects a dynamic equilibrium among three interacting components: (1) vector ecology and environmental suitability, (2) host immunity and demographic turnover, and (3) anthropogenic factors including livestock movement. This section examines each component in sequence, then integrates them to explain wave-like re-emergence patterns and the implications of the broader Simbu serogroup context.

3.1. Vector Competence and Environmental Constraints

SBV transmission is tightly linked to the ecology of *Culicoides* biting midges. In Europe, several species within the *Culicoides obsoletus* and *Culicoides pulicaris* complexes have been implicated in SBV transmission [11,12]. Following ingestion of infected blood, the virus replicates within the vector and, after an extrinsic incubation period, is transmitted to new hosts through saliva during subsequent feeding [11,12].

Unlike many arboviruses confined to tropical regions, SBV demonstrated that European *Culicoides* species can sustain viral transmission under temperate climatic conditions, including relatively low temperatures. This adaptation has facilitated the establishment of SBV as an endemic pathogen in Europe [2,6].

3.2. Climate Change and a Year-Round Transmission Potential

Climatic factors play a central role in shaping SBV epidemiology. Temperature influences vector abundance, feeding frequency, and viral replication within the insect. Warmer conditions accelerate the extrinsic incubation period and increase the proportion of infectious vectors, thereby enhancing transmission efficiency [6,23,24].

Recent studies have challenged the traditional concept of a “vector-free period” during winter months. Evidence from Central Europe indicates that *Culicoides* midges remain active at low temperatures and are frequently detected inside livestock buildings, where microclimatic conditions provide refugia [6,25]. This raises the possibility of low-level, continuous transmission during winter, which has important implications for surveillance systems and trade regulations that assume seasonal interruption of virus circulation.

3.3. Livestock Movement and the Role of Trade

The rapid spread of SBV across Europe following its emergence highlighted the potential role of livestock movement and trade networks in facilitating arbovirus dissemination. Although vector-borne transmission is the primary route of infection, movement of infected animals during the viremic phase may contribute to introduction into new areas where competent vectors are present [6,26–28]. A seroprevalence survey in France during winter 2011–2012 documented exposure in cattle and sheep [27], while a bulk milk tank study in the south-west of Ireland showed evidence of SBV infection in dairy herds in 2013 [28]. The epidemiological significance of animal movement is therefore context-dependent and conditional upon the presence of competent vectors at the destination.

Within Europe, the high density of ruminant populations and frequent movement of animals between regions create conditions that favor rapid geographic expansion. In

addition, trade in germplasm (semen and embryos) may pose a theoretical risk, although its epidemiological significance remains less clearly defined.

Beyond Europe, serological evidence of SBV or related viruses has been reported in regions such as Africa and Asia, including Ethiopia and China [6]. While not all reports confirm active viral circulation, these findings raise concerns about silent spread or independent emergence of related Simbu serogroup viruses. The situation in the Middle East, where multiple Simbu serogroup viruses have been detected serologically, further underscores the importance of robust surveillance systems capable of distinguishing between closely related viruses [10].

3.4. Endemic Stability and Wave-like Re-Emergence

Following the initial pandemic phase (2011–2013), SBV became established as an endemic infection in many parts of Europe. Its epidemiology is now characterized by periodic wave-like re-emergence, driven primarily by changes in herd immunity [2,3,6].

After large outbreaks, a high proportion of the ruminant population becomes immune, reducing transmission in subsequent seasons. Over time, however, this population-level immunity declines due to the birth of susceptible animals, replacement of immune individuals, and possible waning of antibody levels. When the proportion of susceptible hosts reaches a critical threshold, and vector activity resumes under favorable climatic conditions, new transmission waves occur [2,6].

This dynamic equilibrium between host immunity and vector activity explains why SBV persists without continuous large-scale outbreaks yet retains the capacity to cause sporadic epidemics of congenital disease, particularly when naïve pregnant animals are exposed.

3.5. Epidemiological Implications of the Simbu Serogroup Context

The epidemiology of SBV cannot be fully understood without considering the broader Simbu serogroup. In regions where multiple Simbu viruses circulate, epidemiological patterns may be more complex due to cross-protective immunity, sequential infections, and serological cross-reactivity.

Evidence from Africa and the Middle East suggests that co-circulation of multiple Simbu serogroup viruses is common, which may alter transmission dynamics and complicate interpretation of serological surveys [9,10]. In contrast, Europe has largely reported SBV as the dominant circulating Simbu virus. However, reliance on non-specific diagnostic tools raises the possibility that additional Simbu viruses may go undetected, particularly if they produce similar clinical outcomes but are not specifically targeted by surveillance programs [9,10].

3.6. Wildlife Hosts: Current Evidence and Research Gaps

Serological evidence indicates that wild ruminants (e.g., red deer, roe deer, wild boar) can be exposed to SBV, but their contribution to viral persistence, spatial spread, and reintroduction into domestic populations is unclear [6,29]. Available European field studies report SBV antibodies in wild ruminants and wild artiodactyls, with seroprevalence varying by species, region, and sampling period [29–31]. However, active viral circulation in wildlife has not been confirmed, and the duration of antibodies in wild species is unknown. Targeted longitudinal studies with repeated sampling of marked individuals are needed to determine whether wildlife can act as a true reservoir or merely as incidental spillover hosts.

4. Diagnosis Challenge in the Simbu Serogroup Context

4.1. Molecular Detection: Strengths and Limitations

Reverse transcription quantitative PCR (RT-qPCR) is the primary method for detecting SBV RNA during acute infection. It provides high sensitivity and specificity when samples are collected during the short viremic phase, typically within a few days post-infection [8,16]. Multiplex RT-qPCR assays have also been developed to enable simultaneous detection and differentiation of SBV and other Simbu serogroup viruses, particularly in regions where co-circulation may occur [26].

However, this narrow diagnostic window represents a major limitation. In adult animals, viraemia is transient, and failure to sample at the appropriate time can lead to false-negative results. This is particularly relevant in field conditions, where clinical signs may be mild or go unnoticed [8].

In cases of congenital infection, molecular detection remains valuable even after maternal viraemia has resolved. Viral RNA can be detected in fetal tissues, especially brain, spinal cord, and meconium. These tissues provide the highest diagnostic yield and are considered optimal for confirming in utero infection [16].

4.2. Retrospective Diagnosis and Fetal Testing

The short duration of viraemia in adult animals makes retrospective diagnosis challenging. In many cases, infection is only recognized after the birth of malformed offspring. Under these circumstances, diagnosis relies on detection of viral RNA in fetal tissues and identification of antibodies in pre-colostral serum. The detection of antibodies in pre-colostral serum is particularly important, as it indicates *in utero* infection, given that maternal antibodies are not transferred across the placenta in ruminants [5,8,32]. Serological investigations in Italy have also confirmed SBV exposure in livestock [33].

4.3. Serological Assays: Utility and Critical Limitations

Serological testing plays a central role in SBV surveillance, particularly for assessing herd immunity and detecting past exposure [34]. Virus neutralization tests (VNT) are the reference standard due to their high specificity and ability to distinguish between closely related viruses [8].

However, VNT requires specialized laboratory facilities and is not suitable for large-scale screening. As a result, enzyme-linked immunosorbent assays (ELISAs), particularly those based on the nucleocapsid (N) protein, are widely used in routine diagnostics [8].

Despite their practicality, commercial ELISAs have important limitations, especially in the context of the Simbu serogroup. Several studies have demonstrated that these assays are not strictly serogroup-specific, leading to cross-reactivity between antibodies directed against different Simbu viruses [9,10,35].

Antigenic Basis of ELISA Cross-Reactivity

The extensive cross-reactivity observed in commercial SBV ELISAs has a well-defined molecular basis. Most assays use recombinant N protein as the antigen, chosen for its high immunogenicity and ease of production [32,36]. However, the N protein is among the most conserved proteins within the Simbu serogroup, exhibiting high amino acid identity across species [8,36]. Phylogenetic analyses have shown that the SBV N gene is most closely related to that of *Shamonda* virus, with nucleotide sequence identities reaching 96.7% [37]. Structural analysis shows that the immunodominant epitopes recognized by host antibodies during infection map to regions of the N protein that are particularly conserved [36]. Consequently, antibodies raised against Akabane, Aino, Shuni, or Shamonda viruses frequently cross-react with SBV N protein in ELISA format [3,36]. Specifically, N-specific monoclonal antibodies

have been shown to detect not only all tested SBV isolates, but also several other viruses of the Simbu serogroup, with one antibody recognizing all tested Simbu serogroup viruses [36]. The Gc glycoprotein, in contrast, shows greater diversity and contains serotype-specific neutralizing epitopes [32,36]. The N-terminal variable part of the Gc protein (Gc head) is highly immunogenic and the major target of neutralizing antibodies [36]. In contrast to N-specific antibodies, Gc-specific monoclonal antibodies detected different SBV isolates as well as two closely related members of the Simbu serogroup, while one antibody showed highly specific reactivity with the homologous SBV strain only [36]. Experimental Gc-based assays achieve improved specificity but are more challenging to produce and may have lower sensitivity. For instance, a recently developed glycoprotein Gc-based triplex ELISA for the detection and differentiation of antibodies against SBV, *Akabane virus* (AKAV), and *Shuni virus* (SHUV) showed overall diagnostic specificities of 84.56% for SBV, 94.68% for AKAV and 89.39% for SHUV, with sensitivities of 89.08%, 69.44% and 84.91%, respectively, and only slight effects of serological cross-reactivity on diagnostic specificity [35].

4.4. Implications for Surveillance and Emerging Virus Detection

The reliance on broadly reactive serological assays in Europe, where SBV is currently considered the dominant Simbu virus, may create a false sense of epidemiological simplicity. Diagnostic test interpretation for Simbu serogroup viruses is complicated by extensive cross-reactivity, as viruses were assigned into this serogroup based on antigenic relatedness [35,38,39]. If additional Simbu serogroup viruses were introduced or emerged locally, they might not be readily distinguished from SBV using standard ELISA-based surveillance. This raises the possibility that new or re-emerging Simbu viruses could circulate undetected, particularly if they cause similar clinical syndromes. Indeed, serological surveys in Africa and the Middle East have demonstrated that co-circulation of multiple Simbu viruses is common, and potential cross-reactivity complicates the interpretation of serological studies in areas where several related viruses may circulate [9,10]. In Israel, for example, two members of this serogroup—Akabane virus and Shuni virus—were recently detected, highlighting that reliance on SBV-specific assays alone can miss co-circulating viruses [10].

To address these challenges, surveillance systems should incorporate confirmatory virus neutralization testing where appropriate, as VNT remains the gold standard for serogroup-specific differentiation due to its superior specificity compared to broadly reactive ELISAs [39]. Additionally, molecular assays capable of differentiating Simbu viruses, such as S-segment-based real-time RT-PCR assays that can detect multiple Simbu serogroup viruses simultaneously, should be integrated into surveillance protocols [39]. Periodic re-assessment of diagnostic tools is essential as new viruses emerge, particularly because further research is required to determine the disease risk posed by novel orthobunyaviruses and how they could challenge current diagnostic and surveillance capabilities [39].

4.5. Recommended Diagnostic Algorithms for Different Clinical Scenarios

Table 3 provides scenario-specific diagnostic recommendations.

Table 3. Recommended diagnostic approaches by clinical scenario.

Clinical Scenario	Primary Diagnostic	Confirmatory/ Supplementary	Sample Type	Timing	Key Considerations
Acute disease in adult (fever, milk drop, diarrhea)	RT-qPCR (blood)	Serology (paired acute/convalescent VNT)	EDTA blood, serum	Viremic window: days 2–6 post-infection	False negatives common if sampled outside viraemia; paired serology essential

Table 3. Cont.

Clinical Scenario	Primary Diagnostic	Confirmatory/ Supplementary	Sample Type	Timing	Key Considerations
Congenital malformation investigation	RT-qPCR (fetal CNS tissue)	Pre-colostral serum VNT	Brain, spinal cord, meconium; pre-suckling blood	At birth/necropsy	CNS tissue highest yield; pre-colostral serology indicates in utero infection
Abortion/stillbirth outbreak	RT-qPCR (pooled fetal tissues) + maternal serology	VNT on fetal thoracic fluid	Brain (pooled if multiple fetuses); maternal serum	Immediately following abortion	Test 3–5 fetuses per cohort; maternal serology indicates exposure timing
Herd seroprevalence survey (endemic setting)	ELISA (N-protein)	VNT on subset (10–20% of positives)	Serum	Any time; ideally pre-breeding	ELISA for screening; VNT for specificity confirmation
Simbu serogroup differentiation (re-search/surveillance)	Multiplex RT-qPCR or VNT panel	Sequencing (S segment)	Blood, CNS tissue, virus isolate	Dependent on study design	VNT required for serogroup-specific serology; NGS for novel variant detection
Trade/certification screening	VNT (gold standard)	RT-qPCR if recent infection suspected	Serum	Pre-movement	ELISA insufficient due to cross-reactivity
Vaccination monitoring	DIVA-compatible assay if available	VNT for titer quantification	Serum	Post-vaccination (2–4 weeks)	Current inactivated vaccines lack DIVA; second-generation vaccines in development

4.6. Genomic Reassortment: Mechanisms and Risks

The tripartite genome of orthobunyaviruses (segments S, M, L) enables reassortment when two related viruses co-infect a single host or vector cell. Reassortment has been documented experimentally and in nature for several orthobunyaviruses and can generate viruses with altered virulence, host range, or antigenic properties. For Simbu serogroup viruses, natural reassortants have been identified, including the emergence of Shamonda virus as a reassortant between SBV-like and Akabane-like ancestors. The M segment, encoding the Gn and Gc glycoproteins, is the primary determinant of serotype and cell tropism, while the S segment (encoding N and NSs) influences immune evasion capacity [4]. Should SBV co-circulate with another Simbu virus in Europe (e.g., through introduction via live-stock trade), reassortment could theoretically generate novel variants with unpredictable phenotypes. Systematic genomic surveillance is required to detect such events.

4.7. Technical Pathways for Diagnostic Optimization

Several specific technical pathways could improve diagnostic specificity while maintaining practicality for field use:

- (1) **Peptide-based multiplex serology** using a Luminex assay with variable regions of N and Gc proteins from multiple Simbu viruses.
- (2) **NSs antibody detection**—the NSs protein is less conserved and may provide more specific serological markers.
- (3) **Two-tier diagnostic algorithm**—initial screening with N-ELISA followed by reflex VNT or molecular testing.
- (4) **Point-of-care molecular differentiation** using isothermal amplification (e.g., LAMP) with species-specific primers.
- (5) **Artificial intelligence-assisted serology**—machine learning classifiers trained on cross-reactivity patterns to probabilistically assign the most likely infecting virus.

5. Control Gap: Vaccination, Vector Management, and Policy Constraints

5.1. Vaccination: From Rapid Development to Limited Implementation

The emergence of SBV in 2011 triggered an unusually rapid vaccine development response, leading to the availability of several inactivated whole-virus vaccines within a few years, including in the UK following marketing authorization by the Veterinary Medicines Directorate [3,40]. These vaccines demonstrated good efficacy in experimental conditions, significantly reducing or preventing viraemia following challenge and thereby limiting the risk of transplacental transmission [3].

Despite this initial success, vaccination has not been sustained as a routine control strategy in most European countries. Commercial vaccines were progressively withdrawn from the market due to declining demand, reflecting a broader challenge in managing endemic diseases that produce intermittent rather than continuous losses [3,6,41].

5.2. Drivers of Low Vaccine Uptake

In endemic settings, the perceived need for vaccination is strongly influenced by the sporadic nature of clinical disease. Following large outbreaks, herd immunity increases, and the incidence of congenital malformations declines. During these periods, farmers may perceive vaccination as unnecessary, particularly when acute disease in adult animals is mild or subclinical [2,6].

Economic considerations also play a critical role. Vaccination requires direct costs (vaccine purchase) and indirect costs (labor, animal handling, logistics). In extensive production systems, where animals are not frequently handled, these costs may outweigh perceived benefits, especially in years without visible disease impact. In the UK, for example, a study of sheep farmers found that while low perceived disease risk was the main reason for not vaccinating (58%), the majority of farmers would only vaccinate if the cost was £1 or less, and fewer than 15% would vaccinate if the cost exceeded £2, indicating that cost sensitivity is a major barrier after risk perception [41].

Field experience supports this pattern. A UK sheep-farmer survey conducted after the 2016–2017 re-emergence reported limited previous vaccine use and showed that willingness to vaccinate was strongly influenced by vaccine cost [41]. Similar patterns of low uptake have been reported in endemic settings when perceived disease risk is low and vaccine availability is limited [3,6,42].

Table 4 quantifies the contribution of different factors.

Table 4. Qualitative synthesis of factors contributing to low Schmallenberg virus vaccine uptake in endemic settings.

Factor	Qualitative Contribution to Low Uptake	Evidence Base/Interpretation	Practical Implication
Perceived low disease risk	Major driver	In endemic settings, clinical disease is intermittent and congenital cases may occur only after periods of renewed susceptibility. After large outbreaks, farmers may perceive vaccination as unnecessary when visible disease declines.	Risk communication should emphasize cyclical re-emergence, herd immunity decline, and the vulnerability of naive breeding females.

Table 4. *Cont.*

Factor	Qualitative Contribution to Low Uptake	Evidence Base/Interpretation	Practical Implication
Direct vaccine cost	Important economic barrier	Willingness to vaccinate is strongly influenced by vaccine price, especially in low-margin sheep and extensive ruminant systems.	Subsidies, risk-based support, or targeted vaccination of high-risk groups may improve uptake.
Labour and animal-handling costs	Important operational barrier	Vaccination requires gathering, restraint, and administration; these costs are proportionally higher in extensive grazing systems.	Vaccination campaigns should be aligned with routine handling, breeding preparation, or other scheduled flock/herd management procedures.
Vaccine availability and logistics	Context-dependent barrier	Withdrawal or limited availability of commercial vaccines reduces practical access even when farmers or veterinarians are willing to vaccinate.	Vaccine banks or advance procurement mechanisms may help maintain preparedness.
Veterinarian recommendation and farmer awareness	Moderate but modifiable factor	Uptake is influenced by whether farmers receive clear, timely advice on SBV risk, breeding timing, and vaccination value.	Continuing veterinary education and decision-support tools could improve risk-based recommendations.
Concerns about vaccine use in breeding or pregnant animals	Minor to moderate barrier	Although inactivated vaccines are generally considered suitable for use in breeding animals, uncertainty or hesitancy may reduce uptake.	Communication should distinguish clearly between licensed vaccine safety data and unsupported safety concerns.
Lack of DIVA compatibility	Mainly relevant to surveillance and trade	First-generation inactivated vaccines do not readily distinguish vaccinated from naturally infected animals serologically.	DIVA-compatible vaccines and companion diagnostics would improve compatibility with surveillance and certification programmes.

5.3. Limitations of First-Generation Vaccines

Inactivated vaccines, although effective, present several limitations that constrain their long-term use. One of the most important is the lack of DIVA (Differentiating Infected from Vaccinated Animals) capability, as vaccinated animals develop antibodies against the same viral proteins as naturally infected animals [3]. This complicates surveillance programs, certification of disease-free status, and international trade. Additionally, inactivated vaccines often require booster doses and may involve production constraints associated with handling live virus under high-containment conditions [3].

5.4. Emerging Vaccine Platforms and Practical Barriers

Second-generation vaccines, such as NSs-deletion mutants, subunit vaccines targeting the Gc glycoprotein, virus-like particles, and mRNA platforms, offer theoretical advantages including DIVA compatibility [3,42–44]. The N-terminal domain of the Gc glycoprotein has been shown to be essential for neutralization, providing a target for subunit vaccine development [36]. However, several barriers remain: platform-specific regulatory data requirements for novel vaccine technologies [45], limited long-term safety data in food-

producing animals, uncertainty regarding duration of immunity, and lack of accompanying diagnostic tools for full DIVA implementation.

Table 5 provides a comparative analysis of second-generation platforms and their bottlenecks.

Table 5. Comparative analysis of second-generation SBV vaccine platforms after removal of unsupported timeline estimates.

Platform	Advantages	Main Production or Implementation Bottleneck	Evidence for Duration of Protection	DIVA Compatibility	Regulatory or Validation Considerations
NSs-deletion modified-live vaccine	Strong immunogenicity; potential for single-dose protection; possible DIVA compatibility.	Requires robust attenuation, genetic-stability testing, biosafety assessment and controlled production of live virus.	Experimental challenge data are supportive, but long-term field duration data remain limited.	Yes, in principle, if companion serology distinguishes anti-NSs responses.	Requires platform-specific assessment of safety, stability, shedding and reversion-to-virulence risk.
Subunit vaccine based on recombinant Gc	No infectious virus; targets neutralizing epitopes; potentially suitable for breeding animals.	Antigen yield, formulation, adjuvant selection and booster requirements may limit field practicality.	Experimental data support immunogenicity and protection, but field duration remains uncertain.	Potentially yes, if used with a compatible companion diagnostic assay.	Requires validated potency assays, manufacturing consistency and companion diagnostic development.
Virus-like particles (VLPs)	Non-replicating platform; presents viral antigens in a native-like structure; DIVA-compatible design is possible.	Assembly, purification, scale-up and batch-to-batch consistency remain important production challenges.	Evidence is mainly experimental; duration under field conditions remains to be established.	Yes, depending on antigen design and diagnostic strategy.	Requires detailed characterization of particles, quality control and target-species safety evaluation.
mRNA lipid-nanoparticle vaccine	Rapid design and manufacture; no infectious SBV; antigen sequence can be updated quickly.	LNP production, stability, storage requirements, dose optimization and target-species data are limiting factors.	No SBV-specific livestock field duration data are available; duration would need dedicated studies.	Yes, in principle, if the encoded antigen and companion assay are selected accordingly.	Requires platform-specific quality, safety and immunogenicity data for veterinary use.
Viral-vector vaccine	Single-dose potential; no replication-competent SBV; compatible with targeted antigen delivery.	Vector selection, pre-existing vector immunity, manufacturing scale-up and insert stability require evaluation.	Experimental evidence is supportive for some vector approaches, but field duration remains insufficiently defined.	Yes, if vector and insert design allow differentiation from natural infection.	Requires assessment of vector safety, shedding, recombination risk and target-species safety.

5.5. Vector Management: Opportunities and Constraints

In the absence of widespread vaccination, vector control becomes an important component of SBV management. Integrated vector management (IVM) strategies aim to reduce contact between *Culicoides* midges and susceptible hosts through chemical, environmental, and physical interventions [11,24–26].

5.5.1. Production System-Specific Vector Management

Table 6 summarizes recommendations for different farming systems.

Table 6. Production system-specific vector management recommendations.

Intervention	Intensive Dairy (Confined Housing)	Extensive Beef (Pasture-Based)	Sheep/Goat (Mixed System)
Housing management	High feasibility: insect screening, fans, daily manure removal	Low feasibility: animals on pasture 24/7	Moderate: night housing during peak vector season
Insecticide application	Topical pour-ons every 2–4 weeks; premise spraying	Low feasibility; slow-release ear tags may help	Seasonal pour-ons synchronized with handling
Repellents	Not needed (housed)	Limited data; DEET-based: 4–6 h protection	Same as extensive beef
Breeding site reduction	High feasibility: manure management, drainage	Low-moderate: limited control over pasture wetlands	Same as extensive beef
Biosecurity (stabling during risk periods)	N/A (already housed)	Low feasibility for entire herd; possible for high-value stock	Moderate: house pregnant animals during critical windows
Timing of breeding	Adjust calving to avoid late gestation during peak vector activity	Same but implementation challenging	Same; more feasible due to shorter gestation

5.5.2. Insecticide Resistance: Current Status and Mitigation

While baseline susceptibility data for *Culicoides obsoletus* to pyrethroids have been established—demonstrating high toxicity with a deltamethrin LD50 of $1.33 \times 10^{-4}\%$ [46]—susceptibility has been shown to vary at the species and population level across Europe and Africa [47]. Evidence suggests that resistance may be developing in some European *Culicoides* populations, and recent studies have validated methods—such as the adapted WHO susceptibility test—for monitoring this trend [46]. Given these findings, recommended mitigation strategies include: rotation of insecticide classes, maintenance of untreated refugia, systematic resistance surveillance using standardized bioassays, integration of non-chemical control methods (e.g., environmental management) to reduce insecticide use by 50–70%, and threshold-based application (e.g., treating only when vector abundance exceeds 50 midges per trap-night during critical gestational periods).

5.6. Limitations of Vector-Only Strategies

Experience with SBV and other *Culicoides*-borne diseases, such as bluetongue, indicates that vector control alone is insufficient to prevent virus transmission at the population level [11]. Furthermore, evidence of vector activity during winter months within livestock buildings suggests that transmission may occur even when outdoor vector activity is reduced [6,26]. This challenges traditional assumptions about seasonal control and highlights the limitations of relying solely on vector-based interventions.

5.7. Bridging the Implementation Gap: Policy and Strategic Approaches

Potential approaches include: targeted vaccination strategies focusing on naïve replacement animals and breeding females prior to pregnancy; development and maintenance of vaccine banks for rapid deployment during high-risk periods; improved risk communication to farmers; and strengthening public–private partnerships to ensure sustained availability of vaccines and diagnostics. Surveillance systems that integrate entomological, climatic, and serological data can support early warning frameworks [6,48].

5.8. Control Strategies in the Context of the Simbu Serogroup

If additional Simbu viruses are introduced or emerge in Europe, existing vaccination and diagnostic approaches may prove insufficient. Limited experimental data suggest that prior infection with one Simbu virus provides only partial, incomplete cross-protection. Sequential infection studies in cattle have shown that *Akabane* virus-immune animals remain susceptible to SBV, and vice versa. This lack of robust cross-protection means that herd immunity calculated based on SBV seroprevalence may overestimate protection against other Simbu viruses, and vaccination against SBV alone will not necessarily protect against related viruses.

6. Future Challenges and Research Priorities

Fifteen years after its emergence, SBV is firmly established as an endemic pathogen across much of Europe, yet several fundamental questions remain unresolved. These challenges are organized into five dimensions.

6.1. Virological and Etiological Dimensions

- **Reassortment potential:** Targeted full-genome sequencing of SBV from regions where other Simbu viruses may co-circulate (e.g., Mediterranean Basin, potential introduction points). Experimental co-infection studies in *Culicoides* cell lines to assess reassortment frequency.
- **Genetic determinants of virulence and host range:** Reverse genetics studies comparing SBV isolates from different eras and regions.

6.2. Vector Ecology and Environmental Dimensions

- **Winter vector activity:** Year-round light trap collections from livestock buildings with SBV RT-qPCR on pooled midges. Stochastic modelling comparing seasonal vs. continuous transmission scenarios.
- **Climate change impacts:** Predictive modelling under RCP 4.5 and 8.5 scenarios.
- **Insecticide resistance surveillance:** Establish a European network using standardized WHO-type bioassays for *Culicoides*.

6.3. Diagnostic Dimensions

- **Serogroup-specific serological assays:** Develop and validate peptide-based multiplex Luminex assays or NSs-based ELISAs.
- **Multiplex molecular platforms:** Field-deployable LAMP assays for SBV, *Akabane*, *Shuni*, and *Aino* viruses.
- **Two-tier surveillance algorithm:** Routine N-ELISA screening followed by reflex VNT or sequencing of a representative subset.

6.4. Vaccine Development and Deployment Dimensions

- **Second-generation vaccine platforms:** Prioritize DIVA-compatible platforms (NSs-deletion, VLP, mRNA) with parallel development of companion diagnostic assays.
- **Vaccine banks:** Establish a European SBV vaccine bank with predefined deployment triggers and cost-sharing mechanisms.
- **Duration of immunity studies:** Long-term field trials (≥ 2 years) with repeated challenges.

6.5. Policy, Economic, and One Health Dimensions

- **Sustainable vaccination incentives:** Explore co-financing models, risk-based premiums, or subsidized vaccines for high-risk herds.

- **Integrated surveillance frameworks:** Link veterinary, entomological, climatic, and wildlife data streams into a real-time risk mapping platform.
- **Cross-sectoral coordination:** Annual One Health risk assessment meetings; trigger-based response protocols; farmer decision support tools.

One Health Implementation: Specific Measures

Moving beyond conceptual invocation of One Health [49], the following specific measures should be implemented:

- **Cross-sectoral surveillance platform** linking veterinary, entomological, climatic, and wildlife data with FAIR data standards.
- **Annual cross-sectoral risk assessment meeting** with representatives from veterinary authorities, public health (preparedness for zoonotic arboviruses), agricultural economics, and climate services.
- **Trigger-based response protocols** (e.g., seroprevalence > 15%, vector abundance > 50/trap/night, transmission suitability index > 0.7) activating enhanced surveillance, farmer alerts, targeted vaccination, and movement restrictions.
- **European SBV vaccine bank** with defined governance, deployment rules, and cost-sharing.
- **Sentinel site network** (10–15 sites across Europe) with integrated quarterly livestock serology, weekly vector trapping, microclimate monitoring, and annual wildlife sampling.
- **Farmer decision support tools** (mobile-accessible) integrating local SBV risk scores, gestational calendars, and cost–benefit calculators.
- **Mandatory veterinary continuing education** on emerging arboviruses, Simbu serogroup differential diagnosis, and One Health surveillance principles.

7. Conclusions

Schmallenberg virus has evolved from an emerging arboviral threat into an endemic pathogen that continues to challenge livestock health systems across Europe. While its acute clinical impact in adult animals is generally limited, its capacity to induce severe congenital malformations underscores its persistent economic and welfare significance.

This review highlights three central aspects that define the current understanding of SBV. First, its pathogenesis is driven by efficient immune evasion and marked fetal neurotropism, mechanisms that are shared across the Simbu serogroup and complicate clinical differentiation. Second, significant diagnostic limitations remain, particularly due to serological cross-reactivity among related viruses and the narrow window for molecular detection, raising concerns about the potential under-recognition of co-circulating or emerging Simbu viruses. Third, despite substantial advances in vaccine development, a clear implementation gap persists, with limited uptake and availability of vaccines and constrained effectiveness of vector control strategies.

Taken together, these factors illustrate that SBV is not a resolved problem, but a dynamic and evolving system shaped by interactions between host immunity, vector ecology, and environmental change. In this context, SBV provides a valuable model for understanding the emergence, persistence, and control of arboviruses in temperate regions. Future progress will depend on integrating improved diagnostic specificity, sustainable vaccination strategies, and enhanced surveillance systems capable of detecting shifts in virus circulation. Addressing these challenges will be essential not only for the management of SBV but also for strengthening preparedness against future vector-borne disease threats in an increasingly climate-sensitive world.

Author Contributions: Conceptualization, S.P. and V.C.; visualization, A.-R.A., C.S. and L.D.P.; Writing—original draft, S.P., A.-R.A., C.S. and L.D.P.; Writing—review & editing, S.P., Y.L. and V.C.; supervision, Y.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study.

Acknowledgments: The authors would like to thank Ennio Cuteri for creating the graphic abstract and the Figures, generated using the AI Gemini 3 pro image preview tool. The authors have reviewed and edited the output and take full responsibility for the content of this publication.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

SBV	Schmallenberg virus
N	Nucleocapsid protein
NSs	Non-structural protein
IFN	Interferon
NGS	Next-generation sequencing
VNT	Virus neutralization tests
ELISA	Enzyme-linked immunosorbent assays
DIVA	Differentiating Infected from Vaccinated Animals
IVM	Integrated vector management

References

- Hoffmann, B.; Scheuch, M.; Höper, D.; Jungblut, R.; Holsteg, M.; Schirrmeier, H.; Eschbaumer, M.; Goller, K.V.; Wernike, K.; Fischer, M.; et al. Novel Orthobunyavirus in Cattle, Europe, 2011. *Emerg. Infect. Dis.* **2012**, *18*, 469–472. [\[CrossRef\]](#)
- Wernike, K.; Conraths, F.; Zanella, G.; Granzow, H.; Gache, K.; Schirrmeier, H.; Valas, S.; Staubach, C.; Marianneau, P.; Kraatz, F.; et al. Schmallenberg virus—two years of experiences. *Prev. Vet. Med.* **2014**, *116*, 423–434. [\[CrossRef\]](#)
- Wernike, K.; Aebischer, A.; Audonnet, J.-C.; Beer, M. Vaccine Development against Schmallenberg Virus: From Classical Inactivated to Modified-Live to Scaffold Particle Vaccines. *One Health Outlook* **2022**, *4*, 13. [\[CrossRef\]](#) [\[PubMed\]](#)
- Elliott, R.M. Orthobunyaviruses: Recent Genetic and Structural Insights. *Nat. Rev. Microbiol.* **2014**, *12*, 673–685. [\[CrossRef\]](#) [\[PubMed\]](#)
- Lear, A.S.; Abuelo, A. Akabane and Related Simbu Serogroup Virus Infections in Ruminants. In *Merck Veterinary Manual*; Merck & Co., Inc.: Rahway, NJ, USA, 2025. Available online: <https://www.merckvetmanual.com> (accessed on 27 March 2026).
- Wang, J.; Jia, Q.; Xiang, H.; Wang, F.; Sun, C.; Chang, J.; Jiang, Z.; Yin, X. Schmallenberg Virus Epidemiology and Regional Control Strategies: Diagnostics, Vaccines, and Vector Management. *Front. Cell. Infect. Microbiol.* **2025**, *15*, 1633030. [\[CrossRef\]](#)
- Varela, M.; Schnettler, E.; Caporale, M.; Murgia, C.; Barry, G.; McFarlane, M.; McGregor, E.; Piras, I.M.; Shaw, A.; Lamm, C.; et al. Schmallenberg Virus Pathogenesis, Tropism and Interaction with the Innate Immune System of the Host. *PLoS Pathog.* **2013**, *9*, e1003133. [\[CrossRef\]](#) [\[PubMed\]](#)
- Wernike, K.; Beer, M. Schmallenberg Virus: A Novel Virus of Veterinary Importance. *Adv. Virus Res.* **2017**, *99*, 39–60. [\[CrossRef\]](#)
- Mathew, C.; Klevar, S.; Elbers, A.R.W.; van der Poel, W.H.M.; Kirkland, P.D.; Godfroid, J.; Mdegela, R.H.; Mwamengele, G.; Stokstad, M. Detection of Serum Neutralising Antibodies to Simbu Serogroup Viruses in Cattle in Tanzania. *BMC Vet. Res.* **2015**, *11*, 208. [\[CrossRef\]](#)
- Brenner, J.; Yanase, T.; Kato, T.; Khinich, E.; Tsuda, T.; Behar, A. Serological Evidence Suggests That Several Simbu Serogroup Viruses Circulated in Israel. *Vet. Ital.* **2019**, *55*, 81–89. [\[CrossRef\]](#)
- Carpenter, S.; Groschup, M.H.; Garros, C.; Felipe-Bauer, M.L.; Purse, B.V. *Culicoides* Biting Midges, Arboviruses and Public Health in Europe. *Antivir. Res.* **2013**, *100*, 102–113. [\[CrossRef\]](#)

12. De Regge, N.; Deblauwe, I.; De Deken, R.; Vantieghem, P.; Madder, M.; Geysen, D.; Smeets, F.; Losson, B.; van den Berg, T.; Cay, A.B. Detection of Schmallenberg Virus in Different *Culicoides* spp. by Real-Time RT-PCR. *Transbound. Emerg. Dis.* **2012**, *59*, 471–475. [[CrossRef](#)]
13. Wernike, K.; Hoffmann, B.; Bréard, E.; Bötner, A.; Ponsart, C.; Zientara, S.; Lohse, L.; Pozzi, N.; Viarouge, C.; Sarradin, P.; et al. Schmallenberg Virus Experimental Infection of Sheep. *Vet. Microbiol.* **2013**, *166*, 461–466. [[CrossRef](#)] [[PubMed](#)]
14. Linden, A.; Desmecht, D.; Volpe, R.; Wirtgen, M.; Grégoire, F.; Pirson, J.; Paternostre, J.; Kleijnen, D.; Schirrmeier, H.; Beer, M.; et al. Epizootic Spread of Schmallenberg Virus among Wild Cervids, Belgium, Fall 2011. *Emerg. Infect. Dis.* **2012**, *18*, 2006–2008. [[CrossRef](#)]
15. Claine, F.; Coupeau, D.; Wiggers, L.; Muylkens, B.; Kirschvink, N. Schmallenberg Virus Infection of Ruminants: Challenges and Opportunities for Veterinarians. *Vet. Med. Res. Rep.* **2015**, *6*, 261–272. [[CrossRef](#)]
16. Bilk, S.; Schulze, C.; Fischer, M.; Beer, M.; Hlinak, A.; Hoffmann, B. Organ Distribution of Schmallenberg Virus RNA in Malformed Newborns. *Vet. Microbiol.* **2012**, *159*, 236–238. [[CrossRef](#)]
17. Herder, V.; Wohlsein, P.; Peters, M.; Hansmann, F.; Baumgärtner, W. Salient lesions in domestic ruminants infected with the emerging so-called Schmallenberg virus in Germany. *Vet. Pathol.* **2012**, *49*, 588–591. [[CrossRef](#)]
18. Barry, G.; Varela, M.; Ratniner, M.; Blomström, A.L.; Caporale, M.; Seehusen, F.; Hahn, K.; Schnettler, E.; Baumgärtner, W.; Kohl, A.; et al. NSs Protein of Schmallenberg Virus Counteracts the Antiviral Response of the Cell by Inhibiting Its Transcriptional Machinery. *J. Gen. Virol.* **2014**, *95*, 1640–1646. [[CrossRef](#)] [[PubMed](#)]
19. Blomström, A.L.; Gu, Q.; Barry, G.; Wilkie, G.; Skelton, J.K.; Baird, M.; McFarlane, M.; Schnettler, E.; Elliott, R.M.; Palmarini, M.; et al. Transcriptome Analysis Reveals the Host Response to Schmallenberg Virus in Bovine Cells and Antagonistic Effects of the NSs Protein. *BMC Genom.* **2015**, *16*, 324. [[CrossRef](#)] [[PubMed](#)]
20. Golender, N.; Bumbarov, V.; Assis, I.; Beer, M.; Khinich, Y.; Koren, O.; Edery, N.; Eldar, A.; Wernike, K. Shuni virus in Israel: Neurological disease and fatalities in cattle. *Transbound. Emerg. Dis.* **2019**, *66*, 1126–1131. [[CrossRef](#)]
21. Guis, H.; Caminade, C.; Calvete, C.; Morse, A.P.; Tran, A.; Baylis, M. Modelling the effects of past and future climate on the risk of bluetongue emergence in Europe. *J. R. Soc. Interface* **2012**, *9*, 339–350. [[CrossRef](#)]
22. Sick, F.; Breithaupt, A.; Golender, N.; Bumbarov, V.; Beer, M.; Wernike, K. Shuni virus-induced meningoencephalitis after experimental infection of cattle. *Transbound. Emerg. Dis.* **2021**, *68*, 1531–1540. [[CrossRef](#)]
23. Gale, P.; Drew, T.; Phipps, L.P.; David, G.; Wooldridge, M. The Effect of Climate Change on the Occurrence and Prevalence of Livestock Diseases in Great Britain: A Review. *J. Appl. Microbiol.* **2009**, *106*, 1409–1423. [[CrossRef](#)] [[PubMed](#)]
24. Groschupp, S.; Kampen, H.; Werner, D. Winter activity of *Culicoides* (Diptera: Ceratopogonidae) inside and outside stables in Germany. *Med. Vet. Entomol.* **2024**, *38*, 552–565. [[CrossRef](#)] [[PubMed](#)]
25. Kameke, D.; Kampen, H.; Walther, D. Activity of *Culicoides* spp. (Diptera: Ceratopogonidae) inside and outside of livestock stables in late winter and spring. *Parasitol. Res.* **2017**, *116*, 881–889. [[CrossRef](#)]
26. Lee, J.H.; Seo, H.J.; Park, J.Y.; Kim, S.H.; Cho, Y.S.; Kim, Y.J.; Cho, I.S.; Jeoung, H.Y. Detection and Differentiation of Schmallenberg, Akabane and Aino Viruses by One-Step Multiplex Reverse-Transcriptase Quantitative PCR Assay. *BMC Vet. Res.* **2015**, *11*, 270. [[CrossRef](#)]
27. Gache, K.; Dominguez, M.; Pelletier, C.; Petit, E.; Calavas, D.; Hendrikx, P.; Touratier, A. Schmallenberg virus: A seroprevalence survey in cattle and sheep, France, winter 2011–2012. *Vet. Rec.* **2013**, *173*, 141. [[CrossRef](#)]
28. Johnson, A.; Bradshaw, B.; Boland, C.; Ross, P. A bulk milk tank study to detect evidence of spread of Schmallenberg virus infection in the south-west of Ireland in 2013. *Ir. Vet. J.* **2014**, *67*, 11. [[CrossRef](#)]
29. Garcia-Bocanegra, I.; Cano-Terriza, D.; Vidal, G.; Rosell, R.; Paniagua, J.; Jiménez-Ruiz, S.; Expósito, C.; Rivero, A.; Arenas, A.; Pujols, J. Monitoring of Schmallenberg virus in Spanish wild artiodactyls, 2006–2015. *PLoS ONE* **2017**, *12*, e0182212. [[CrossRef](#)]
30. Larska, M.; Krzysiak, M.K.; Kęsik-Maliszewska, J.; Rola, J. Cross-sectional study of Schmallenberg virus seroprevalence in wild ruminants in Poland at the end of the vector season of 2013. *BMC Vet. Res.* **2014**, *10*, 967. [[CrossRef](#)]
31. Wernike, K.; Fischer, L.; Holsteg, M.; Aebischer, A.; Petrov, A.; Marquart, K.; Schotte, U.; Schön, J.; Hoffmann, D.; Hechinger, S.; et al. Serological screening in wild ruminants in Germany, 2021/2022: No evidence of SARS-CoV-2, bluetongue virus or pestivirus spread but high seroprevalences against Schmallenberg virus. *Transbound. Emerg. Dis.* **2022**, *69*, e3289–e3296. [[CrossRef](#)]
32. Bréard, E.; Lara, E.; Comtet, L.; Viarouge, C.; Doceul, V.; Desprat, A.; Vitour, D.; Pozzi, N.; Cay, A.B.; De Regge, N.; et al. Validation of a Commercially Available Indirect ELISA Using a Nucleocapsid Recombinant Protein for Detection of Schmallenberg Virus Antibodies. *PLoS ONE* **2013**, *8*, e53446. [[CrossRef](#)]
33. Foxi, C.; Pintus, D.; Zinellu, S.; Macciocu, S.; Angioi, P.P.; Sechi, A.M.; Fiori, M.S.; Ladu, A.; Puggioni, G.; Denti, S.; et al. Assessing Schmallenberg virus disease in Sardinia (Italy) after the first epidemic episode in 2012. *Pathogens* **2025**, *14*, 349. [[CrossRef](#)]
34. Veldhuis, A.M.B.; van Schaik, G.; Vellema, P.; Elbers, A.R.W.; Bouwstra, R.; van der Heijden, H.M.J.F.; Mars, M.H. Schmallenberg Virus Epidemic in the Netherlands: Spatiotemporal Introduction in 2011 and Seroprevalence in Ruminants. *Prev. Vet. Med.* **2013**, *112*, 35–47. [[CrossRef](#)] [[PubMed](#)]

35. Wernike, K.; Aebischer, A.; Sick, F.; Szillat, K.P.; Beer, M. Differentiation of Antibodies against Selected Simbu Serogroup Viruses by a Glycoprotein Gc-Based Triplex ELISA. *Vet. Sci.* **2021**, *8*, 12. [\[CrossRef\]](#)
36. Wernike, K.; Aebischer, A.; Roman-Sosa, G.; Beer, M. The N-terminal domain of Schmallerberg virus envelope protein Gc is highly immunogenic and can provide protection from infection. *Sci. Rep.* **2017**, *7*, 42500. [\[CrossRef\]](#)
37. Goller, K.V.; Höper, D.; Schirmer, H.; Mettenleiter, T.C.; Beer, M. Schmallerberg virus as possible ancestor of Shamonda virus. *Emerg. Infect. Dis.* **2012**, *18*, 1644–1646. [\[CrossRef\]](#) [\[PubMed\]](#)
38. O'Connor, T.W.; Hick, P.M.; Finlaison, D.S.; Kirkland, P.D.; Toribio, J.-A.L.M.L. Revisiting the Importance of Orthobunyaviruses for Animal Health: A Scoping Review of Livestock Disease, Diagnostic Tests, and Surveillance Strategies for the Simbu Serogroup. *Viruses* **2024**, *16*, 294. [\[CrossRef\]](#)
39. Golender, N.; Bumbarov, V.Y.; Erster, O.; Beer, M.; Khinich, Y.; Wernike, K. Development and validation of a universal S-segment-based real-time RT-PCR assay for the detection of Simbu serogroup viruses. *J. Virol. Methods* **2018**, *261*, 80–85. [\[CrossRef\]](#)
40. Veterinary Medicines Directorate. Veterinary Medicines Guidance Notes. 2024. Available online: <https://www.gov.uk/government/collections/veterinary-medicines-guidance-notes-vmgns> (accessed on 27 March 2026).
41. Stokes, J.E.; Tarlinton, R.E.; Lovatt, F.; Baylis, M.; Carson, A.; Duncan, J.S. Survey to determine the farm-level impact of Schmallerberg virus during the 2016–2017 United Kingdom lambing season. *Vet. Rec.* **2018**, *183*, 690. [\[CrossRef\]](#)
42. Wernike, K.; Beer, M. Schmallerberg virus: To vaccinate, or not to vaccinate? *Vaccines* **2020**, *8*, 287. [\[CrossRef\]](#)
43. Pardi, N.; Hogan, M.J.; Porter, F.W.; Weissman, D. mRNA Vaccines—A New Era in Vaccinology. *Nat. Rev. Drug Discov.* **2018**, *17*, 261–279. [\[CrossRef\]](#)
44. Bettini, E.; Locci, M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. *Vaccines* **2021**, *9*, 147. [\[CrossRef\]](#)
45. European Medicines Agency. *Guideline on Data Requirements for Vaccine Platform Technology Master Files (vPTMF)*; EMA/CVMP/IWP/105506/2020; European Medicines Agency: Amsterdam, The Netherlands, 2024. Available online: https://doi.org/www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-vaccine-platform-technology-master-files-vptmf_en.pdf (accessed on 13 July 2026).
46. Del Río, R.; Venail, R.; Calvete, C.; Barceló, C.; Baldet, T.; Lucientes, J.; Miranda, M.A. Sensitivity of *Culicoides obsoletus* (Meigen) (Diptera: Ceratopogonidae) to deltamethrin determined by an adapted WHO standard susceptibility test. *Parasitology* **2014**, *141*, 542–546. [\[CrossRef\]](#)
47. Venail, R.; Lhoir, J.; Fall, M.; del Río, R.; Talavera, S.; Labuschagne, K.; Miranda, M.; Pagès, N.; Venter, G.; Rakotoarivony, I.; et al. How do species, population and active ingredient influence insecticide susceptibility in *Culicoides* biting midges (Diptera: Ceratopogonidae) of veterinary importance? *Parasit. Vectors* **2015**, *8*, 439. [\[CrossRef\]](#)
48. Roberts, H.C.; Elbers, A.R.W.; Conraths, F.J.; Holsteg, M.; Höreth-Böntgen, D.; Gethmann, J.; van Schaik, G. Response to an emerging vector-borne disease: Surveillance and preparedness for Schmallerberg virus. *Prev. Vet. Med.* **2014**, *116*, 341–349. [\[CrossRef\]](#) [\[PubMed\]](#)
49. Mackenzie, J.S.; Jeggo, M. The One Health Approach—Why Is It So Important? *Trop. Med. Infect. Dis.* **2019**, *4*, 88. [\[CrossRef\]](#)

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.